Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
1.
Int J Neurosci ; 129(5): 447-454, 2019 May.
Artigo em Inglês | MEDLINE | ID: mdl-30366515

RESUMO

BACKGROUND: Glioblastoma multiforme (GBM) patients with a prior malignancy are usually excluded from clinical trials on GBM based on the assumption that this history will affect their survival outcomes. This practice may affect clinical trial accrual and limit the gathering of knowledge essential to the formulation of therapeutic options for this patient population. However, not much is known about the real impact of these prior malignancies on the survival of patients with subsequent GBM. We aimed to investigate the degree of such an impact. PATIENTS AND METHODS: We used the Surveillance, Epidemiology, and End Results (SEER) Program to analyze data of GBM patients diagnosed between 1973 and 2014. We calculated the overall and GBM-specific survival of these patients using the unadjusted Kaplan-Meier test and the multivariable covariate-adjusted Cox models. RESULTS: Of 51,158 GBM patients, 3,076 had a prior malignancy. The unadjusted Kaplan-Meier test showed worse overall and GBM-specific survivals for patients who had a prior history of cancer. However, after adjusting for age at diagnosis of GBM, sex, race, marital status, and conduction of surgery, multivariable covariate-adjusted Cox models showed that having a prior malignancy did not significantly affect neither overall survival (HR = 1.025, 95%CI = .986 - 1.066, p = .213) nor GBM-specific survival (HR = 1.005, 95%CI = .963 - 1.049, p = .810). CONCLUSIONS: Our findings suggest that the broad practice of excluding patients with a prior history of cancer should be reconsidered as it may adversely affect accrual, trial completion rates, and generalizability of the results.


Assuntos
Neoplasias Encefálicas/mortalidade , Glioblastoma/mortalidade , Segunda Neoplasia Primária/mortalidade , Sistema de Registros , Análise de Sobrevida , Adolescente , Adulto , Fatores Etários , Idoso , Feminino , Humanos , Estimativa de Kaplan-Meier , Masculino , Pessoa de Meia-Idade , Modelos de Riscos Proporcionais , Adulto Jovem
2.
Clin Anat ; 30(2): 251-266, 2017 03.
Artigo em Inglês | MEDLINE | ID: mdl-27997062

RESUMO

The intervertebral disc (IVD) is a joint unique in structure and functions. Lying between adjacent vertebrae, it provides both the primary support and the elasticity required for the spine to move stably. Various aspects of the IVD have long been studied by researchers seeking a better understanding of its dynamics, aging, and subsequent disorders. In this article, we review the surgical anatomy, imaging modalities, and molecular biology of the lumbar IVD. Clin. Anat. 30:251-266, 2017. © 2017 Wiley Periodicals, Inc.


Assuntos
Disco Intervertebral/embriologia , Humanos , Disco Intervertebral/diagnóstico por imagem , Vértebras Lombares , Imageamento por Ressonância Magnética
4.
BMJ Evid Based Med ; 28(2): 126-132, 2023 04.
Artigo em Inglês | MEDLINE | ID: mdl-36732029

RESUMO

OBJECTIVES: To empirically evaluate five commonly used meta-analysis methods and their impact on imprecision judgements about effect estimates. The two fixed-effect model methods were the inverse variance method based on normal distribution and the Mantel-Haenszel method. The three random-effects model methods were the DerSimonian and Laird, the Hartung-Knapp-Sidik-Jonkman and the profile likelihood approaches. DESIGN: Meta-epidemiological study. SETTING: Meta-analyses published between 2007 and 2019 in the 10 general medical journals with the highest impact factors that evaluated a medication or device for chronic medical conditions and included at least 5 randomised trials. MAIN OUTCOME MEASURES: Discordance in the judgements of imprecision of effect estimates based on two definitions: when either boundary of 95% CI of the OR changed by more than 15% or changed in relation to the null. RESULTS: We analysed 88 meta-analyses including 1114 trials with an average of 12.60 trials per meta-analysis and average I2 of 26% (range: 0%-96%). The profile likelihood failed to converge in three meta-analyses (3%). Discordance in imprecision judgements based on the two definitions, respectively, occurred between the fixed normal distribution and fixed Mantel-Haenszel method (8% and 2%), between the DerSimonian and Laird and Hartung-Knapp-Sidik-Jonkman methods (19% and 10%), between the DerSimonian and Laird and profile likelihood methods (9% and 5%), and between the Hartung-Knapp-Sidik-Jonkman and profile likelihood methods (5% and 13%). Discordance was greater when fewer studies and greater heterogeneity was present. CONCLUSION: Empirical evaluation of studies of chronic medical conditions showed that conclusions about the precision of the estimates of the efficacy of a drug or device frequently changed when different pooling methods were used, particularly when the number of studies within a meta-analysis was small and statistical heterogeneity was substantial. Sensitivity analyses using more than one method may need to be considered in these two scenarios.


Assuntos
Julgamento , Projetos de Pesquisa , Humanos , Funções Verossimilhança , Tamanho da Amostra , Estudos Epidemiológicos
5.
BMJ Case Rep ; 20162016 Jan 13.
Artigo em Inglês | MEDLINE | ID: mdl-26762347

RESUMO

Hashimoto encephalopathy (HE) is a controversial autoimmune disorder, probably underdiagnosed, that causes a wide variety of neurological manifestations. Symptoms differ among patients and may be very severe in some cases. However, it can be treated, with a very good prognosis. In our case, a teenaged girl with a family history of migraine, vitiligo and benign paroxysmal positional vertigo presented with severe ataxia, vomiting and hypotension. She had a history of similar, but milder, symptoms and was misdiagnosed several times. She had subclinical hypothyroidism, and high levels of antithyroid antibodies. There were abnormal MRI and visual evoked potential findings. After excluding other more common causes, we diagnosed her as having 'Hashimoto Encephalopathy', and started treatment with corticosteroids, on which she showed dramatic improvement. After about 2 years of presentation, the patient is able to continue her life independently.


Assuntos
Encefalopatias/diagnóstico , Encefalite/diagnóstico , Glucocorticoides/uso terapêutico , Doença de Hashimoto/diagnóstico , Adolescente , Ataxia/etiologia , Diagnóstico Diferencial , Encefalite/tratamento farmacológico , Feminino , Doença de Hashimoto/tratamento farmacológico , Humanos , Hipotensão/etiologia , Imageamento por Ressonância Magnética , Peroxidases/imunologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA